DexCom, Inc. reported second-quarter 2025 adjusted earnings per share of 48 cents, surpassing projections by 6.7%. This figure was an increase from the previous year’s EPS of 43 cents.<\/p>\n
Revenues rose 15.2% to $1.16 billion, exceeding expectations by 3.1%. Growth was driven by strong demand, particular success in type 2 diabetes sectors, and recent access wins.<\/p>\n
Despite these results, DXCM shares fell by 5.5% post-trading on 30 July, although they have risen 9.9% this year. This is against the backdrop of a 7.3% decline in the industry.<\/p>\n
The sensor and other revenues, forming 97% of total revenues, grew by 18% to $1.12 billion. In contrast, hardware revenues decreased by 31% to $39.3 million.<\/p>\n
U.S. revenues increased 15% to $841 million, while international revenues grew 16% to $316.1 million. However, the adjusted gross margin fell to 60.1%, down by 340 basis points year over year.<\/p>\n
DexCom reported a 9% rise in research and development expenses to $148.2 million. Adjusted operating income increased by 13.5% to $221.8 million, with margins slightly down.<\/p>\n
The company anticipates 2025 revenues of $4.6-$4.625 billion, reflecting a 14-15% growth. The gross margin is expected to reach approximately 62%.<\/p>\n
Product innovation includes the upcoming 15-day G7 sensor, and over 400,000 downloads of the new Stelo biosensor app. Moreover, they are launching an AI-powered Smart Food Logging feature for enhanced diabetes management.<\/p>\n
Despite near-term margin pressures, the company remains optimistic about gross margin guidance. Kevin Sayer will step down as CEO in early 2026, with Jake Leach set to succeed him.<\/p>\n
The proposed competitive bidding program for Medicare CGM could pose challenges, but DexCom remains confident with its strong market position. The company is expanding with access to approximately 6 million new lives, aiming for 25 million. With significant cash reserves and a growing customer base, DexCom is well-positioned in the CGM market.<\/p>\n
We are observing a classic “sell the news” scenario with DexCom following its July 30th earnings report. Despite beating revenue and earnings estimates, the stock’s 5.5% drop signals that the market is focused on shrinking gross margins. This pressure on profitability is the key takeaway for us, outweighing the strong top-line growth for now.<\/p>\n
From a derivatives standpoint, this event has significantly altered the options landscape. Implied volatility for DXCM, which we saw spike to over 60% before the announcement, has already started to contract sharply toward the 45% level. This post-earnings volatility crush means selling options premium is becoming more attractive than buying it.<\/p>\n
The market’s concern over margins is amplified by external factors. Reports from mid-July 2025 confirmed that key competitor Abbott received an accelerated FDA review for its next-generation Libre 4 sensor, fueling worries about a price war. We believe this backdrop makes it unlikely that DXCM shares will break out to new highs in the immediate term.<\/p>\n
Looking back at the stock’s history, we saw similar post-earnings dips in both late 2023 and mid-2024. In those instances, strong user growth was also overshadowed by concerns about future profitability, leading to short-term weakness. This historical pattern suggests the current pullback is a recurring theme rather than a new crisis.<\/p>\n
Given the strong underlying growth drivers like the new Stelo biosensor and expanding market access, a complete collapse in the stock price seems unlikely. The sell-off may present an opportunity for strategies that bet on a price floor, such as selling out-of-the-money put spreads. This allows us to collect premium while defining our risk, should the margin concerns cause further temporary dips.<\/p>\n
For the coming weeks, we anticipate the stock will likely enter a consolidation phase as traders weigh the positive sales growth against the negative margin pressure. The upcoming CEO transition in 2026 adds another layer of long-term uncertainty but should have minimal impact on short-term trading. Therefore, we are considering strategies that profit from the stock trading within a defined range.<\/p>\n","protected":false},"excerpt":{"rendered":"
DexCom posts strong Q2 earnings and revenue growth, eyes innovation, but shares dip on margin concerns.<\/p>\n","protected":false},"author":62,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[59],"tags":[],"class_list":["post-27852","post","type-post","status-publish","format-standard","hentry","category-live-updates"],"acf":{"acf_article_selection_author":null},"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.vtmarkets.com\/en-asia\/wp-json\/wp\/v2\/posts\/27852","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.vtmarkets.com\/en-asia\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.vtmarkets.com\/en-asia\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.vtmarkets.com\/en-asia\/wp-json\/wp\/v2\/users\/62"}],"replies":[{"embeddable":true,"href":"https:\/\/www.vtmarkets.com\/en-asia\/wp-json\/wp\/v2\/comments?post=27852"}],"version-history":[{"count":0,"href":"https:\/\/www.vtmarkets.com\/en-asia\/wp-json\/wp\/v2\/posts\/27852\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.vtmarkets.com\/en-asia\/wp-json\/wp\/v2\/media?parent=27852"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.vtmarkets.com\/en-asia\/wp-json\/wp\/v2\/categories?post=27852"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.vtmarkets.com\/en-asia\/wp-json\/wp\/v2\/tags?post=27852"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}